You are viewing a version of a model that has been updated. To access the latest version, and a more detailed display please go here.

Grange2001 - PK interaction of L-dopa and benserazide

View the 2013-05 Model of the Month entry for this model
  public model
Short description

This the compartmental model from the article:
A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats.
Grange S, Holford NH and Guentert TW. Pharm Res. 2001 AUg; 18(8):1174-84 11587490,
Abstract:
PURPOSE: To study the PK interaction of L-dopa/benserazide in rats. METHODS: Male rats received a single oral dose of 80 mg/kg L-dopa or 20 mg/kg benserazide or 80/20 mg/kg L-dopa/benserazide. Based on plasma concentrations the kinetics of L-dopa, 3-O-methyldopa (3-OMD), benserazide, and its metabolite Ro 04-5127 were characterized by noncompartmental analysis and a compartmental model where total L-dopa clearance was the sum of the clearances mediated by amino-acid-decarboxylase (AADC), catechol-O-methyltransferase and other enzymes. In the model Ro 04-5127 inhibited competitively the L-dopa clearance by AADC.
RESULTS: The coadministration of L-dopa/benserazide resulted in a major increase in systemic exposure to L-dopa and 3-OMD and a decrease in L-dopa clearance. The compartmental model allowed an adequate description of the observed L-dopa and 3-OMD concentrations in the absence and presence of benserazide. It had an advantage over noncompartmental analysis because it could describe the temporal change of inhibition and recovery of AADC.
CONCLUSIONS: Our study is the first investigation where the kinetics of benserazide and Ro 04-5127 have been described by a compartmental model. The L-dopa/benserazide model allowed a mechanism-based view of the L-dopa/benserazide interaction and supports the hypothesis that Ro 04-5127 is the primary active metabolite of benserazide.

Format
SBML (L2V4)
Related Publication
  • A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats.
  • Grange S, Holford NH, Guentert TW
  • Pharmaceutical research , 8/ 2001 , Volume 18 , pages: 1174-1184
  • PRNS Non-Clinical Drug Safety, F. Hoffmann-La Roche Ltd, Basel, Switzerland. susan.grange@roche.com
  • PURPOSE: To study the PK interaction of L-dopa/benserazide in rats. METHODS: Male rats received a single oral dose of 80 mg/kg L-dopa or 20 mg/kg benserazide or 80/20 mg/kg L-dopa/benserazide. Based on plasma concentrations the kinetics of L-dopa, 3-O-methyldopa (3-OMD), benserazide, and its metabolite Ro 04-5127 were characterized by noncompartmental analysis and a compartmental model where total L-dopa clearance was the sum of the clearances mediated by amino-acid-decarboxylase (AADC), catechol-O-methyltransferase and other enzymes. In the model Ro 04-5127 inhibited competitively the L-dopa clearance by AADC. RESULTS: The coadministration of L-dopa/benserazide resulted in a major increase in systemic exposure to L-dopa and 3-OMD and a decrease in L-dopa clearance. The compartmental model allowed an adequate description of the observed L-dopa and 3-OMD concentrations in the absence and presence of benserazide. It had an advantage over noncompartmental analysis because it could describe the temporal change of inhibition and recovery of AADC. CONCLUSIONS: Our study is the first investigation where the kinetics of benserazide and Ro 04-5127 have been described by a compartmental model. The L-dopa/benserazide model allowed a mechanism-based view of the L-dopa/benserazide interaction and supports the hypothesis that Ro 04-5127 is the primary active metabolite of benserazide.
Contributors
Lukas Endler

Metadata information

Curation status
Curated
Name Description Size Actions

Model files

BIOMD0000000320.xml.origin SBML L2V4 representation of Grange2001 - PK interaction of L-dopa and benserazide 17.39 KB Preview | Download

  • Model originally submitted by : Lukas Endler
  • Submitted: Oct 29, 2009 5:40:51 PM
  • Last Modified: May 18, 2017 12:31:53 PM
Revisions
  • Version: 2 public model Download this version
    • Submitted on: May 18, 2017 12:31:53 PM
    • Submitted by: Lukas Endler
    • With comment: Current version of Grange2001 - PK interaction of L-dopa and benserazide
  • Version: 1 public model Download this version
    • Submitted on: Oct 29, 2009 5:40:51 PM
    • Submitted by: Lukas Endler
    • With comment: Original import of Grange2001_L_Dopa_comp_model
Curator's comment:
(added: 28 Mar 2011, 00:19:15, updated: 28 Mar 2011, 00:19:15)
Time courses for a dose of 80/20mg/kg L-Dopa/Benserazide as in figures 5 and 7 of the original article. The results were calculated using Copasi 4.6.33.
Due to problems with the use of initial assignments in Copasi, the model has to be evaluated once using either a short time-course simulation or a steady state computation to calculate and assign the correct starting values. After this, the model reproduces the correct results. Future versions of Copasi should not have this problem. The model was also tested with SBW 2.7.10, which did not exhibit this problem.